Plain-English translation of NCT07373288 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying a molecule called HOXB7 and related markers found in lung tissue and blood to better understand pulmonary fibrosis—a condition where lung tissue becomes scarred and stiff. By analyzing tissue samples from biopsies and blood-derived particles called exosomes, the team hopes to identify new signs that could help detect and track disease progression earlier.
Pulmonary fibrosis is difficult to diagnose and monitor because doctors currently rely on limited tools. This study seeks to discover new biological markers in tissue and blood that could serve as early warning signs of disease progression, potentially leading to better detection methods and treatment opportunities in the future.
You likely qualify if…
You likely don't qualify if…
If you qualify, researchers will collect small samples of your lung tissue during a biopsy or surgery you are already having for clinical reasons, plus a blood sample. The study also includes a comparison group of patients undergoing lung surgery for other conditions (like cancer suspicion). Your samples will be analyzed using specialized laboratory techniques to identify disease markers; there are no additional visits or experimental treatments involved.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Italy
Sponsor
University of Modena and Reggio Emilia
Enrollment target
~80 participants
Started
July 2023
Primary completion
July 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Roberto Tonelli
University of Modena and Reggio Emilia
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.